CRISPR Therapeutics(NASDAQ) CRSP

CRISPR Therapeutics AG makes gene-based medicines for serious diseases. It fixes the genetic code to treat blood disorders and cancer. This helps patients with few other options.

Medicine for the Genetic Level

• Hemoglobinopathy Therapies: Treatments for sickle cell disease and beta thalassemia, including CASGEVY, which edits cells outside the body to boost healthy hemoglobin levels.
• In Vivo Liver Editing: Pipeline of therapies delivered directly into the body to fix genes associated with cardiovascular and metabolic diseases.
• CAR-T Cell Therapies: Genetically engineered immune cells designed to target specific cancers and autoimmune conditions like lupus.
• Regenerative Medicine: Development of insulin-producing cell replacements for patients living with type 1 diabetes to restore normal body function.

Expanding the Treatment Pipeline

• Secured the first global approval for a CRISPR-based therapy, CASGEVY, in 2023.
• Partnered with Sirius Therapeutics in May 2025 to develop treatments using small interfering RNA technology.
• Expanded the FDA approval for CASGEVY in July 2026 to include pediatric patients as young as 2 years old.
• Entered a clinical collaboration with Eli Lilly to study cell therapies in combination with existing cancer drugs.

Unique Operational Strengths

The company operates its own manufacturing facility in Massachusetts to produce its engineered cell therapies for clinical trials. It uses specialized delivery technologies and its SyNTase gene correction platform to target diseases in the liver and other specific organs.

Recent Financial Performance

• Total revenue was $11.6 million for the six-month period ended June 30, 2026, primarily from a one-time licensing payment.
• Net loss for the six-month period ended June 30, 2026, was $214.1 million.
• Cash, cash equivalents, and marketable securities totaled $2.4 billion as of June 30, 2026.
• Net proceeds from the issuance of convertible senior notes reached $585.4 million in March 2026.
• Market capitalization was $5.3 billion in the second quarter of 2026, up 24.3% year over year.

Bottom Line

CRISPR Therapeutics has evolved from a discovery-stage startup to a commercial-stage leader in genetic medicine. Its transition to selling approved therapies while maintaining a broad research pipeline demonstrates its ability to bring complex technologies to the healthcare market.